Changes in ganglion cell layer thickness after treatment with the 0.2 µg/day fluocinolone acetonide implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema
Conclusion: There was no evident retinal neurodegeneration in the 2-year period following treatment with FAc in both groups. GCL thickness may be a useful biomarker for assessing safety and effectiveness in patients with DME.
Source: Ophthalmic Research - Category: Opthalmology Source Type: research
More News: Brain | Diabetes | Endocrinology | Eye Implants | Eyes | Ganglions | Neurology | Opthalmology | Study | Vitamin A